Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02756286 · ClinicalTrials.gov registry record
Neurophysiological Attention Test (NAT) for Objective Assessment of Adult ADHD
A clinical trial of Attention Deficit Hyperactivity Disorder, sponsored by Think Now Incorporated.
- Completed
- Registry status
- 258
- Enrollment target
- 3
- Study locations
NCT02756286: Completed study of Attention Deficit Hyperactivity Disorder, sponsored by Think Now Incorporated.
NCT02756286 is a study of Attention Deficit Hyperactivity Disorder that has completed, run by Think Now Incorporated. The registered enrollment target is 258 participants, above the 214-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (21% higher). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02756286, a study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by Think Now Incorporated.
- COMPLETED
- Registry status
- 258 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to refine a new assessment tool for Attention Deficit/Hyperactivity Disorder (ADHD) and then to test its validity (i.e. ability to discriminate between individuals with ADHD and healthy controls.
Primary Outcome
The NAT EEG test simultaneously generates 2 EEG values and 1 behavioral value that are used together as an assessment metric for ADHD. This is a one-time measure to assess its magnitude in ADHD vs Control.
Conditions Studied
Interventions
- OTHER NAT electroencephalography (EEG) test
Study Locations (3)
California
- University of California Berkeley - Berkeley
- UCLA Semel Institute - Los Angeles
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2018-07-05 |
What the finished NCT02756286 record still lists
NCT02756286 is an observational study that tracks outcomes without assigning an intervention. The registered 258 participants enrollment target is mid-sized for trials with a published cap, above the 214-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (21% higher).
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 1 intervention - of which NAT electroencephalography (EEG) test is the first listed.
NCT02756286 reports a single indexed study location in California, Oregon.
Frequently Asked Questions
What is clinical trial NCT02756286 about?
NCT02756286 is a clinical study titled "Neurophysiological Attention Test (NAT) for Objective Assessment of Adult ADHD". The purpose of this study is to refine a new assessment tool for Attention Deficit/Hyperactivity Disorder (ADHD) and then to test its validity (i.e. ability to discriminate between individuals with ADHD and healthy controls.
What is the current status of trial NCT02756286?
This trial is currently completed. The enrollment target is 258 participants. The study started on 2017-01-01. Estimated completion is 2018-07-05.
What conditions does trial NCT02756286 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT02756286?
The interventions under investigation include: NAT electroencephalography (EEG) test (OTHER).
Who is sponsoring clinical trial NCT02756286?
This trial is sponsored by Think Now Incorporated, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02756286 being conducted?
This trial has 3 study locations across California, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02756286's enrollment target sits among peer trials
258 24th of 102 higher than 79 of 102 other Attention Deficit Hyperactivity Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Developing Brain, Impulsivity and Compulsivity
RECRUITING
-
HOPS Study: A Conceptual Replication
RECRUITING · NA
-
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
RECRUITING · Phase 4
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Acute Effects of Exercise in College Students With ADHD
RECRUITING · NA
-
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03785288 · 258 participants · Phase 3
Vaginal Cuff Brachytherapy Fractionation Study
- NCT04643002 · 258 participants · Phase 1
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
- NCT04924322 · 258 participants · Phase 2
Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies
- NCT05043012 · 258 participants · NA
Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI